Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. 

On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while maintaining a Neutral rating, reflecting a selective stance toward SMID-cap biotech heading into 2026. While Citi sees opportunity in commercial or near-commercial stage companies, its broader outlook favored other names, highlighting the importance of upcoming clinical and regulatory catalysts in determining relative upside across the space.

More recently, Arcturus announced the initiation of a first-in-human Phase 1 study for ARCT-2304, a self-amplifying mRNA-based pandemic influenza vaccine. For investors, this represents an early but meaningful inflection point, as it will provide initial human data on whether Arcturus’ proprietary self-amplifying RNA platform can demonstrate competitive immune responses with potentially lower dosing requirements. While any commercial contribution remains several years away, positive safety and immunogenicity data could materially improve Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s strategic positioning by supporting future partnerships, grant funding, or non-dilutive capital. Until clinical results are disclosed, the shares are likely to remain range-bound, with sentiment driven by expectations around data timing and management commentary.

Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is an RNA medicines biotechnology company focused on developing therapies and vaccines for rare diseases and infectious diseases, leveraging its differentiated RNA technology platform to target large, long-term market opportunities.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.